Kyprolis 60 mg Injection: Advanced Proteasome Inhibitor Therapy
Extensive Product Profile: Understanding Kyprolis 60 mg InjectionKyprolis 60 mg Injection contains Carfilzomib, an advanced anti-cancer medication that acts as a selective proteasome inhibitor.
1. Clinical Indications & Usage
- Multiple Myeloma Management: Indicated for patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
- Tumor Lysis Prevention: Acts directly on malignant plasma cells in the bone marrow to control disease progression and alleviate bone pain.
2. Mechanism of Action: How Kyprolis Works
Kyprolis works through a highly specific pharmacological pathway:- Proteasome Inhibition: Carfilzomib binds irreversibly to the N-terminal threonine-containing active sites of the 20S proteasome in the cell.
- Protein Accumulation: By suppressing the normal degradation of intracellular proteins, it causes an accumulation of misfolded proteins, triggering cell cycle arrest and apoptosis (programmed cell death) of malignant cells.
3. Administration and Dosing Guide
- Administration Route: Administered via intravenous (IV) infusion over 10 to 30 minutes, depending on the dosage regimen prescribed by an oncologist.
- Pre-medication: Often administered with Dexamethasone and adequate intravenous hydration to reduce the incidence and severity of infusion-related reactions and tumor lysis syndrome.
- Contraindications & Precautions: Not recommended for use during pregnancy.
Both male and female patients must use effective contraception during and for several months following treatment.
Safety, Side Effects, and Monitoring
- Hematologic Monitoring: Routine assessment of complete blood count (CBC) is necessary due to the risk of thrombocytopenia and neutropenia.
- Common Side Effects: Fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, and fever.
- Toxicity Management: Patients must be monitored for signs of cardiac events (heart failure, ischemia), pulmonary toxicity, and hepatic or renal impairment. Dosage reduction or interruption may be clinically indicated.
Why Partner with Ernest Impex for Global Sourcing?
Sourcing through Ernest Impex ensures you receive professional-grade, secured supply-chain services:
- Traceability: Every shipment is provided with a full Certificate of Analysis (COA) and complete batch traceability.
- Regulatory Support: We facilitate document clearance and supply chain logistics in compliance with TGA, HSA, and US-FDA/MHRA guidelines.
- Cold-Chain Integrity: Packed in strict compliance with cold-chain protocols (stored between
$2^\circ\text{C}$ and $8^\circ\text{C}$) to prevent degradation from temperature variations or light exposure. - Secure Bulk Supply: Consistent inventory availability for institutional healthcare tenders, pharmacies, and specialty clinics.
Sales, Pricing, and Market Insights
- B2B / Wholesale Price Range: Bulk procurement prices for verified Indian manufacturers and distributors for the Kyprolis brand range from βΉ35,000 to βΉ44,367 per vial, while alternative or generic Carfilzomib brands (such as Carfilnat or Carzomib) range from βΉ4,400 to βΉ10,000 per vial depending on volume, brand, and export taxes.
- Storage and Logistics Requirements: Must be stored between
$2^\circ\text{C}$ and $8^\circ\text{C}$ (refrigerated; do not freeze). Protect from light.
π Contact Ernest Impex β Pharmaceutical Exporter from India
www.ernestimpex.com www.ernestvision.com www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com